POLYMORPHISM IN K-RAS 3 UNTRANSLATED REGION ASSOCIATED WITH CLINICAL OUTCOMES OF CANCER TREATMENTS INDEPENDENT OF K-RAS MUTATION STATUS

• 收藏
• 分享

专利权人:

Heinz-Josef Lenz

发明人:

Heinz-Josef Lenz

申请号：

US13278101

公开号：

US20120107309A1

申请日:

2011.10.20

申请国别(地区):

US

年份:

2012

代理人:

摘要：

The invention provides compositions and methods for determining the likelihood of response or survival of cancer patients treated with anti-EGFR therapy, topoisomerase inhibitor therapy or anti-EGFR therapy/topoisomerase inhibitor therapy combination therapy. After determining if a patient is likely to be successfully treated, the invention also provides methods for treating the patients.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/